- Home
- HLVX vs IOBT Comparison
HLVX vs IOBT Comparison
Compare HLVX & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- IOBT
- Stock Information
- Founded
- HLVX 2020
- IOBT 2014
- Country
- HLVX United States
- IOBT Denmark
- Employees
- HLVX N/A
- IOBT N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- IOBT Health Care
- Exchange
- HLVX Nasdaq
- IOBT Nasdaq
- Market Cap
- HLVX 87.6M
- IOBT 81.7M
- IPO Year
- HLVX 2022
- IOBT 2021
- Fundamental
- Price
- HLVX $1.89
- IOBT $0.89
- Analyst Decision
- HLVX Hold
- IOBT Strong Buy
- Analyst Count
- HLVX 5
- IOBT 3
- Target Price
- HLVX $2.33
- IOBT $9.33
- AVG Volume (30 Days)
- HLVX 124.1K
- IOBT 279.8K
- Earning Date
- HLVX 11-07-2024
- IOBT 11-12-2024
- Dividend Yield
- HLVX N/A
- IOBT N/A
- EPS Growth
- HLVX N/A
- IOBT N/A
- EPS
- HLVX N/A
- IOBT N/A
- Revenue
- HLVX N/A
- IOBT N/A
- Revenue This Year
- HLVX N/A
- IOBT N/A
- Revenue Next Year
- HLVX N/A
- IOBT N/A
- P/E Ratio
- HLVX N/A
- IOBT N/A
- Revenue Growth
- HLVX N/A
- IOBT N/A
- 52 Week Low
- HLVX $1.55
- IOBT $0.73
- 52 Week High
- HLVX $20.22
- IOBT $2.10
- Technical
- Relative Strength Index (RSI)
- HLVX 50.42
- IOBT 33.52
- Support Level
- HLVX $1.80
- IOBT $0.86
- Resistance Level
- HLVX $2.02
- IOBT $1.29
- Average True Range (ATR)
- HLVX 0.08
- IOBT 0.12
- MACD
- HLVX 0.01
- IOBT -0.04
- Stochastic Oscillator
- HLVX 41.86
- IOBT 7.15
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.